A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.

Key facts

Study ID

NCT00977522

Run by

Pfizer

People needed

207

Starts

2009-11-01

Expected to finish

2010-09-01

Last updated by the study team

2012-02-07

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have a current diagnosis of schizophrenia of paranoid (295.30), disorganized (295.10), or undifferentiated (295.90) subtype in the residual phase.
• Subjects must be in ongoing maintenance antipsychotic monotherapy with risperidone, olanzapine, quetiapine, ziprasidone, paliperidone, or aripiprazole. Subjects must be on a stable medication treatment regimen for at least 2 months.
• Evidence of stable symptomatology at least 3 months.

You may not qualify if…

• Female subjects who are pregnant or breastfeeding.
• Subjects with evidence or history of a clinically significant medical condition which would increase risk or which could interfere with the interpretation of trial results.
• Subjects who have DSM IV defined psychoactive substance dependence (including alcohol and excluding nicotine and caffeine dependence) within 12 months of screening or substance abuse within 3 months prior to screening.

Where it is running

• Pfizer Investigational Site — Cerritos, California, United States
• Pfizer Investigational Site — Chula Vista, California, United States
• Pfizer Investigational Site — Escondido, California, United States
• Pfizer Investigational Site — Garden Grove, California, United States
• Pfizer Investigational Site — Glendale, California, United States
• Pfizer Investigational Site — Long Beach, California, United States
• Pfizer Investigational Site — Long Beach, California, United States
• Pfizer Investigational Site — National City, California, United States
• Pfizer Investigational Site — Paramount, California, United States
• Pfizer Investigational Site — Torrance, California, United States
• Pfizer Investigational Site — Washington D.C., District of Columbia, United States
• Pfizer Investigational Site — Washington D.C., District of Columbia, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Decatur, Georgia, United States
• Pfizer Investigational Site — Park Ridge, Illinois, United States
• Pfizer Investigational Site — Wichita, Kansas, United States
• Pfizer Investigational Site — Wichita, Kansas, United States
• Pfizer Investigational Site — Flowood, Mississippi, United States
• Pfizer Investigational Site — Las Vegas, Nevada, United States
• Pfizer Investigational Site — Las Vegas, Nevada, United States
• Pfizer Investigational Site — Runnemede, New Jersey, United States
• Pfizer Investigational Site — Toms River, New Jersey, United States
• Pfizer Investigational Site — Willingboro, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.